Hologic (HOLX) Receives Daily News Impact Rating of 0.24

Media headlines about Hologic (NASDAQ:HOLX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Hologic earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.1850204840095 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Hologic (HOLX) traded up $0.18 during mid-day trading on Wednesday, hitting $38.96. 68,763 shares of the stock traded hands, compared to its average volume of 2,617,809. Hologic has a one year low of $35.33 and a one year high of $46.80. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The firm has a market cap of $10,720.00, a P/E ratio of 14.80, a price-to-earnings-growth ratio of 1.76 and a beta of 0.84.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same quarter last year, the firm posted $0.52 EPS. Hologic’s revenue was up 7.7% compared to the same quarter last year. equities analysts expect that Hologic will post 2.25 EPS for the current year.

Several analysts have issued reports on HOLX shares. Canaccord Genuity reaffirmed a “buy” rating and set a $48.00 price target on shares of Hologic in a research report on Friday, February 9th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a report on Friday, February 9th. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Thursday, January 4th. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a research note on Wednesday, December 20th. Finally, Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $48.00.

In related news, Director Namal Nawana acquired 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the purchase, the director now owns 6,954 shares in the company, valued at $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.88% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Hologic (HOLX) Receives Daily News Impact Rating of 0.24” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-hologic-holx-share-price/1889635.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.